What strategies—communication about treatment expectations, managing side effects, use of bronchodilators, etc.—do you employ at the front lines of patient management when using amikacin liposome inhalation suspension in MAC lung disease?
What strategies—communication about treatment expectations, managing side effects, use of bronchodilators, and others—do you employ at the front lines of patient management when using amikacin liposome inhalation suspension in MAC lung disease
Created by
Presenter
Director of University of Miami and VA Sarcoidosis Programs
Co-Director UM NTM Program
IRB Vice-Chairman, Miami VA Healthcare System
Assistant Professor of Department of Medicine
Assistant Professor of Clinical Public Health Sciences
Division of Pulmonary